A new drug developed by a company with US headquarters in Raleigh, Ohtuvayre, was approved by the FDA Wednesday to help COPD patients manage symptoms.

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: The CHRONICLES COPD study, officially titled Chronicling ...

The top 5 most-read chronic obstructive pulmonary disease (COPD) articles of 2024 covered topics such as inhaled medication risks, gabapentinoid use, and the link between high white blood cell ...

COPD can make it hard for you to breathe. Learn which treatments can help you get active again.

In the first half of 2024, many posts on X, formerly Twitter, from U.S. health care professionals discussing COPD therapies focused on ventilation support, medications and palliative care ...

COPD “treatment is personalized to an individual’s lung function, symptoms, frequency of exacerbation and markers of inflammation,” says Dr. Conroy.In severe or advanced cases, lung volume ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

A new drug developed by a company with US headquarters in Raleigh, Ohtuvayre, was approved by the FDA Wednesday to help COPD patients manage symptoms.

Factors linked to better inhaled COPD medication adherence in veterans included older age, a higher number of maintenance inhalers used and chronic prednisone use, according to results published ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 ...

"Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034"The chronic obstructive ...